Cuprina Holdings (cayman) vs Pavmed
Pavmed is the larger business, with $71,000 of revenue in fiscal 2025 against $38,204 for Cuprina Holdings (cayman) (1.9 times as much). Cuprina Holdings (cayman) grew faster (5.6% against -97.6%). Pavmed kept more of each dollar of sales as profit: a net margin of 564.8% against -9366.8%.
| Latest fiscal year | Cuprina Holdings (cayman)CUPR, 2025 | PavmedPAVM, 2025 |
|---|---|---|
| Revenue | $38,204 | $71,000 |
| Revenue growth | 5.6% | -97.6% |
| Net income | −$3.6m | $401,000 |
| Operating margin | — | -30712.7% |
| Net margin | -9366.8% | 564.8% |
| Return on equity | — | 2.5% |
| Free cash flow | −$7.0m | −$5.2m |
| Cash | $2.4m | $1.5m |
| Total debt | $128,260 | $7.8m |
| Debt to equity | — | 23.1% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | — | 41 |
| Market value | $37.9m | $11.7m |
| Price vs our value range | — | — |
| Moat score | — | 20 (Weak) |
| Insider trades, 12 months | 0 buys, 0 sales | 0 buys, 0 sales |